Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPHNASDAQ:AURANASDAQ:BGMNASDAQ:ETNB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$8.24+1.5%$8.02$4.99▼$10.67$1.13B1.21.35 million shs1.07 million shsAURAAura Biosciences$5.83+4.9%$6.36$4.84▼$12.38$279.25M0.43202,337 shs161,112 shsBGMQilian International Holding Group$11.12-2.0%$10.48$5.26▼$14.78$1.08B1.3227,998 shs14,580 shsETNB89bio$8.02+6.2%$7.43$4.16▼$11.84$1.17B1.251.33 million shs2.01 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+1.48%+1.85%+2.49%+3.00%+61.89%AURAAura Biosciences+4.86%+1.22%-0.51%-26.48%-21.22%BGMQilian International Holding Group-0.10%+1.65%-2.80%+13.35%+1,111,999,900.00%ETNB89bio+6.23%+21.15%+10.32%-16.80%-5.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals2.6338 of 5 stars3.52.00.00.02.10.81.9AURAAura Biosciences2.3447 of 5 stars3.62.00.00.02.92.50.0BGMQilian International Holding GroupN/AN/AN/AN/AN/AN/AN/AN/AETNB89bio3.0075 of 5 stars4.41.00.00.03.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$11.5039.56% UpsideAURAAura Biosciences 3.25Buy$22.75290.22% UpsideBGMQilian International Holding Group 0.00N/AN/AN/AETNB89bio 2.89Moderate Buy$27.25239.78% UpsideCurrent Analyst Ratings BreakdownLatest AURA, BGM, AUPH, and ETNB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/8/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/26/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$19.003/26/2025AURAAura BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/25/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$25.003/24/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/22/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/14/2025ETNB89bioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$11.003/13/2025ETNB89bioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.003/7/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)2/28/2025ETNB89bioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $21.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$235.13M4.79N/AN/A$2.63 per share3.13AURAAura BiosciencesN/AN/AN/AN/A$4.58 per shareN/ABGMQilian International Holding Group$25.10M43.08N/AN/A$6.10 per share1.82ETNB89bioN/AN/AN/AN/A$5.75 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals-$78.02M$0.05N/A14.71N/A-10.23%-4.41%-3.07%5/1/2025 (Estimated)AURAAura Biosciences-$76.41M-$1.75N/AN/AN/AN/A-41.57%-36.43%5/8/2025 (Estimated)BGMQilian International Holding Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/AETNB89bio-$142.19M-$3.43N/AN/AN/AN/A-59.58%-52.21%5/8/2025 (Estimated)Latest AURA, BGM, AUPH, and ETNB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025AURAAura Biosciences-$0.45N/AN/AN/AN/AN/A5/8/2025Q1 2025ETNB89bio-$0.50N/AN/AN/AN/AN/A5/1/2025Q1 2025AUPHAurinia Pharmaceuticals$0.09N/AN/AN/A$61.06 millionN/A3/24/2025Q4 2024AURAAura Biosciences-$0.43-$0.52-$0.09-$0.52N/AN/A3/6/2025Q4 2024ETNB89bio-$0.60-$1.02-$0.42-$1.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AAURAAura BiosciencesN/AN/AN/AN/AN/ABGMQilian International Holding GroupN/AN/AN/AN/AN/AETNB89bioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.175.605.11AURAAura BiosciencesN/A12.4712.47BGMQilian International Holding GroupN/A3.392.82ETNB89bio0.0911.6611.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%AURAAura Biosciences96.75%BGMQilian International Holding GroupN/AETNB89bioN/AInsider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals4.30%AURAAura Biosciences5.40%BGMQilian International Holding Group58.66%ETNB89bio2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300136.65 million137.02 millionOptionableAURAAura Biosciences5050.23 million47.25 millionNot OptionableBGMQilian International Holding Group29897.22 million2.48 millionN/AETNB89bio40145.98 million103.15 millionOptionableAURA, BGM, AUPH, and ETNB HeadlinesRecent News About These Companies89bio (NASDAQ:ETNB) Stock Price Up 4.5% - Time to Buy?April 30 at 4:55 PM | marketbeat.comRaymond James Financial Inc. Acquires Shares of 377,370 89bio, Inc. (NASDAQ:ETNB)April 30 at 3:48 AM | marketbeat.comBarclays PLC Buys 425,206 Shares of 89bio, Inc. (NASDAQ:ETNB)April 29 at 3:49 AM | marketbeat.com89bio's (ETNB) "Sell (D-)" Rating Reiterated at Weiss RatingsApril 27, 2025 | marketbeat.com89bio, Inc. (NASDAQ:ETNB) Shares Purchased by JPMorgan Chase & Co.April 26, 2025 | marketbeat.comInvestors Buy Large Volume of 89bio Put Options (NASDAQ:ETNB)April 24, 2025 | marketbeat.com89bio (NASDAQ:ETNB) Trading Up 6.1% - Time to Buy?April 23, 2025 | marketbeat.comAvoro Capital Advisors LLC Makes New Investment in 89bio, Inc. (NASDAQ:ETNB)April 23, 2025 | marketbeat.comRock Springs Capital Management LP Makes New Investment in 89bio, Inc. (NASDAQ:ETNB)April 23, 2025 | marketbeat.com89bio Target of Unusually Large Options Trading (NASDAQ:ETNB)April 23, 2025 | americanbankingnews.comGeode Capital Management LLC Grows Position in 89bio, Inc. (NASDAQ:ETNB)April 21, 2025 | marketbeat.comShort Interest in 89bio, Inc. (NASDAQ:ETNB) Grows By 38.3%April 20, 2025 | marketbeat.comQuoc Le-Nguyen Sells 15,329 Shares of 89bio, Inc. (NASDAQ:ETNB) StockApril 18, 2025 | insidertrades.com89bio: A Buy With Strong Market Opportunity In MASH And SHTGApril 18, 2025 | seekingalpha.com89bio: Primary Asset Targeting 2 Potential Indications And Is In Late-Stage DevelopmentApril 17, 2025 | seekingalpha.comUniversity of Wisconsin Foundation Purchases 193,225 Shares of 89bio, Inc. (NASDAQ:ETNB)April 15, 2025 | marketbeat.com89bio, Inc. (NASDAQ:ETNB) Shares Purchased by Alliancebernstein L.P.April 14, 2025 | marketbeat.comVanguard Group Inc. Grows Stock Holdings in 89bio, Inc. (NASDAQ:ETNB)April 14, 2025 | marketbeat.com89bio, Inc. (NASDAQ:ETNB) Given Average Recommendation of "Moderate Buy" by AnalystsApril 13, 2025 | marketbeat.com89bio (NASDAQ:ETNB) Sets New 1-Year Low - Time to Sell?April 12, 2025 | marketbeat.com89bio (NASDAQ:ETNB) Receives Sell (D-) Rating from Weiss RatingsApril 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonDave & Buster’s Stock: A Short-Squeeze PLAY for Q2By Thomas Hughes | April 10, 2025View Dave & Buster’s Stock: A Short-Squeeze PLAY for Q2First Watch Restaurant Group: A First-Rate Small-Cap Growth StockBy Thomas Hughes | April 3, 2025View First Watch Restaurant Group: A First-Rate Small-Cap Growth StockAURA, BGM, AUPH, and ETNB Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$8.24 +0.12 (+1.48%) As of 04/30/2025 04:00 PM EasternAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Aura Biosciences NASDAQ:AURA$5.83 +0.27 (+4.86%) As of 04/30/2025 04:00 PM EasternAura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Qilian International Holding Group NASDAQ:BGM$11.12 -0.23 (-2.03%) As of 04/30/2025 04:00 PM EasternQilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.89bio NASDAQ:ETNB$8.02 +0.47 (+6.23%) As of 04/30/2025 04:00 PM Eastern89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
